Although though we are in the grips of a pandemic and our attention is focused on the development of treatments and vaccines for COVID-19, manufacturing of drug products to treat other conditions is continuing, and GMPs must still be maintained. Sponsor companies continue to manufacture products and are still dependent upon products and services from outsourced suppliers. In the April 2, 2020 issue of PharmTech, Linda Evans O’Connor, VP and Chief of Staff, Lachman Consultants, was interviewed about qualifying suppliers, and covers the frequency of audits, creating a library of CoAs, and how to audit a supplier during times of travel restrictions. If you have any questions or need help auditing a supplier, please contact Linda Evans O’Connor at